The China Alzheimer Report 2022

China’s population has rapidly aged over the recent decades of social and economic development as neurodegenerative disorders have proliferated, especially Alzheimer’s disease (AD) and related dementias (ADRD). AD’s incidence rate, morbidity, and mortality have steadily increased to make it presentl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:General psychiatry 2022-02, Vol.35 (1), p.e100751-e100751
Hauptverfasser: Ren, Rujing, Qi, Jinlei, Lin, Shaohui, Liu, Xinya, Yin, Peng, Wang, Zhihui, Tang, Ran, Wang, Jintao, Huang, Qiang, Li, Jianping, Xie, Xinyi, Hu, Yongbo, Cui, Shishuang, Zhu, Yuan, Yu, Xiaoping, Wang, Pengfei, Zhu, Yikang, Wang, Yiran, Huang, Yanyan, Hu, Yisong, Wang, Ying, Li, Chunbo, Zhou, Maigeng, Wang, Gang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:China’s population has rapidly aged over the recent decades of social and economic development as neurodegenerative disorders have proliferated, especially Alzheimer’s disease (AD) and related dementias (ADRD). AD’s incidence rate, morbidity, and mortality have steadily increased to make it presently the fifth leading cause of death among urban and rural residents in China and magnify the resulting financial burdens on individuals, families and society. The ‘Healthy China Action’ plan of 2019–2030 promotes the transition from disease treatment to health maintenance for this expanding population with ADRD. This report describes related epidemiological trends, evaluates the economic burden of the disease, outlines current clinical diagnosis and treatment status and delineates existing available public health resources. More specifically, it examines the public health impact of ADRD, including prevalence, mortality, costs, usage of care, and the overall effect on caregivers and society. In addition, this special report presents technical guidance and supports for the prevention and treatment of AD, provides expertise to guide relevant governmental healthcare policy development and suggests an information platform for international exchange and cooperation.
ISSN:2517-729X
2096-5923
2517-729X
DOI:10.1136/gpsych-2022-100751